NCT06558708

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

A Phase II Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection and GZR33-70 Injection in Type 2 Diabetes Inadequately Controlled on Basal Insulin or Premixed Insulin Once Daily at Least With or Without Pre-dinner Meal-time Insulin

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Gan and Lee Pharmaceuticals, USA · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in China. The aim of the trial is to compare the efficacy, tolerability, and safety of GZR101 Injection and GZR33-70 Injection in type 2 diabetes inadequately controlled on basal/ premixed insulin once daily at least with or without pre-dinner meal-time insulin.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	GZR101 Injection	Once daily
DRUG	GZR33 Injection	Once daily
DRUG	Insulin aspart	Once daily

Timeline

• Start date: 2024-06-28
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2024-08-19
• Last updated: 2024-08-19

Locations

1 site across 1 country: China